The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
Background Glucagon-like peptide 1 receptor agonists are a class of drug originally developed to treat type 2 diabetes but now increasingly used for weight loss, especially in people living with obesity. Despite an abundance of evidence about the effectiveness and safety of glucagon-like peptide 1 r...
Saved in:
| Main Authors: | Michael Nunns, Samantha Febrey, Jill Buckland, Rebecca Abbott, Rebecca Whear, Alison Bethel, Kate Boddy, Liz Shaw, Jo Thompson Coon, GJ Melendez-Torres |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
NIHR Journals Library
2025-06-01
|
| Series: | Health Technology Assessment |
| Subjects: | |
| Online Access: | https://doi.org/10.3310/SKHT8119 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
by: Sam Febrey, et al.
Published: (2025-04-01) -
Evaluation of the Aspects of Digital Interventions That Successfully Support Weight Loss: Systematic Review With Component Network Meta-Analysis
by: Michael Nunns, et al.
Published: (2025-05-01) -
Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk
by: Gisella Figlioli, et al.
Published: (2024-12-01) -
Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs
by: Rui Gao, et al.
Published: (2024-12-01) -
Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01)